article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

FDA Law Blog: Biosimilars

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Under GDUFA III alone, DPD published 32 GDUFA guidance documents and MAPPs to ensure the successful implementation of GDUFA.

article thumbnail

Reports Document FDA Review Delays: What Drugmakers Should Know Now

FDA Law Blog: Biosimilars

By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Episode 908: Finally, All the VTE Recommendations In One Document!

Pharmacy Joe

Episode 908: Finally, All the VTE Recommendations In One Document! This meant that any unchanged guidance statements from the 2012 9th edition were still considered to be part of the guidelines, but were not reprinted in the 2016 document. appeared first on Pharmacy Joe.

article thumbnail

7 common compliance issues faced by the pharmaceutical industry in India

Express Pharma

Building internal safety protocols and maintaining comprehensive documentation are essential to meet these environmental and safety obligations. Regular audits, proper documentation, and legal vetting of contracts are necessary to avoid such issues. Falling short can mean serious consequences, including product recalls or export bans.

article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

FDA Law Blog: Biosimilars

FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies. It was at this workshop that the agency committed to issuing a draft strategy document, for public comment.

article thumbnail

Warning Letters: An Untapped Source for Understanding When Device Changes Require a New 510(k)

FDA Law Blog: Biosimilars

Manufacturers must evaluate device changes in the first instance to determine whether a new 510(k) is needed or, instead, whether documentation of the change and rationale for not seeking 510(k) clearance is sufficient. See 21 C.F.R. For example, in an October 13, 2023 WL to ReNovo, Inc.,

article thumbnail

Episode 908: Finally, All the VTE Recommendations In One Document!

Pharmacy Joe

Episode 908: Finally, All the VTE Recommendations In One Document! This meant that any unchanged guidance statements from the 2012 9th edition were still considered to be part of the guidelines, but were not reprinted in the 2016 document. appeared first on Pharmacy Joe.